Kestra Medical Technologies (NASDAQ:KMTS) Trading 10.1% Higher – Still a Buy?

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS)’s share price rose 10.1% during mid-day trading on Friday . The stock traded as high as $22.70 and last traded at $22.4750. Approximately 40,446 shares traded hands during trading, a decline of 88% from the average daily volume of 335,844 shares. The stock had previously closed at $20.41.

Analyst Upgrades and Downgrades

KMTS has been the topic of a number of research analyst reports. The Goldman Sachs Group decreased their price target on shares of Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating on the stock in a report on Thursday, April 9th. BTIG Research reiterated a “buy” rating and issued a $32.00 target price on shares of Kestra Medical Technologies in a research report on Tuesday, April 7th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Kestra Medical Technologies in a research note on Monday, March 23rd. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $27.40.

Kestra Medical Technologies Price Performance

The stock has a market capitalization of $1.33 billion and a PE ratio of -5.76. The company has a debt-to-equity ratio of 0.15, a current ratio of 7.32 and a quick ratio of 7.32. The firm’s 50 day simple moving average is $22.17 and its 200 day simple moving average is $24.29.

Kestra Medical Technologies (NASDAQ:KMTS) last announced its quarterly earnings data on Tuesday, March 17th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.01). The business had revenue of $24.55 million during the quarter. Kestra Medical Technologies had a negative net margin of 171.87% and a negative return on equity of 65.49%. Kestra Medical Technologies’s revenue was up 62.7% on a year-over-year basis.

Insider Activity

In other news, insider Brian Daniel Webster sold 15,000 shares of the firm’s stock in a transaction dated Wednesday, April 15th. The stock was sold at an average price of $20.04, for a total transaction of $300,600.00. Following the transaction, the insider directly owned 349,786 shares of the company’s stock, valued at approximately $7,009,711.44. This trade represents a 4.11% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold 45,000 shares of company stock worth $988,650 over the last quarter. 3.60% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Kestra Medical Technologies

Institutional investors have recently bought and sold shares of the stock. Invesco Ltd. purchased a new position in Kestra Medical Technologies in the 4th quarter worth approximately $239,000. Perceptive Advisors LLC purchased a new stake in shares of Kestra Medical Technologies during the fourth quarter valued at approximately $7,558,000. Janus Henderson Group PLC purchased a new stake in shares of Kestra Medical Technologies during the fourth quarter valued at approximately $300,000. Balyasny Asset Management L.P. grew its holdings in shares of Kestra Medical Technologies by 80.6% in the fourth quarter. Balyasny Asset Management L.P. now owns 6,915 shares of the company’s stock worth $183,000 after purchasing an additional 3,086 shares during the last quarter. Finally, Burkehill Global Management LP purchased a new position in shares of Kestra Medical Technologies in the fourth quarter worth $1,326,000.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.